HIV Entry and Its Inhibition

HIV-1 entry into host cells is a complex process driven by the viral envelope protein complex, which consists of the surface subunit gp120 and the transmembrane subunit gp41. In its native state on the virion surface, the envelope complex is metastable. Upon binding to CD4 and a coreceptor on the target cell, gp120 undergoes a conformational change that triggers gp41 to transition into a fusion-active state. This transition involves the exposure of a hydrophobic fusion peptide, which inserts into the target cell membrane, and the subsequent formation of a highly stable six-helix bundle. This structural rearrangement brings the viral and cellular membranes into close proximity, facilitating fusion.

Research has identified that synthetic peptides derived from the heptad repeat regions of gp41 can potently inhibit HIV infection. These C-peptides do not act on the native, non-fusogenic form of the envelope protein. Instead, they target a transient 'prehairpin' intermediate that exists after receptor binding but before the final assembly of the six-helix bundle. By binding to the N-peptide region of this intermediate, C-peptides act through a dominant-negative mechanism, preventing the protein from completing the conformational change necessary for membrane fusion.

Developing an effective HIV vaccine remains a significant challenge due to the virus's ability to evade the immune system. Current evidence suggests that the envelope proteins of clinical HIV isolates are often masked by carbohydrates and that the most effective neutralizing antibodies target rare, conformation-specific epitopes. Past vaccine efforts using monomeric gp120 have largely failed because they often elicit antibodies against denatured or improperly folded proteins rather than the native oligomeric complex found on the virus. Future vaccine strategies must prioritize the use of correctly folded, processed, and stable envelope protein preparations to better mimic the native viral state and potentially elicit more broadly neutralizing responses.